Chief medical Fool Brian Orelli thinks that newly approved multiple sclerosis drug Gilenya from Novartis
Because I use Copaxone, Teva sends me marketing materials and life advice every now and then. The latest missive focused squarely on the rise of Gilenya, which is taken orally, and why I shouldn't rush to adopt this new, unproven, possibly dangerous therapy. The headlines in the newsletter, along with Teva's related arguments, include the following:
- "What we DON'T know" -- Gilenya is presumed to reduce immune cell counts, which can interfere with the body's natural defenses.
- "New vs established" -- "[L]ittle is known about [Gilenya's] long-term safety and efficacy."
- What we DO know -- Copaxone "is trusted, proven, and stands the test of time -- a smart choice in therapy today and well into the future."
Fire up the spinner!
OK, that's just regular marketing spin: point out the negatives of a new competitor while highlighting why your old solution is better. I get it. But the spin machine really goes into overdrive on the next page under the heading, "Let's look at how some people have made Copaxone a positive part of their daily routine." Teva's definition of "positive" is what I'd call "tolerable" at best:
- "It's routine, and it does not interfere with my life."
- "With Copaxone, you can choose when you want to do your daily injection."
- "Taking my shot every day is a part of a program of motivation to stay committed to being on this medicine regimen so I can be present for my kids."
Really, Teva? I log my injections in a nifty day planner Teva sends out every year. The injection pain typically rates between a 2 and a 4 on a 10-point scale, but sometimes it's a lot worse. My needle phobia isn't getting any better after two years of this hassle, and my insurance company gets billed more than $3,700 a month for the privilege of keeping me supplied. It must suck for UnitedHealth Group
All I'm doing is slowing down the progression of my disease on a statistical level with no proof that Copaxone is actually helping me at all. But it's routine, done at my convenience, and I'm motivating myself to stay on the medicine just by doing it -- so it's all right. Right? Yeah, right.
But that's the best Teva can do here. Taking these shots is a hassle for some and a terror for others. There's just no way to make it sound pleasant, even in blatantly sponsored marketing materials. There is so much research activity around MS right now that I can't really fault Teva for running scared. But that's no reason to insult my intelligence like Teva just did.
Teva does have a point, though
I'm not jumping on the Gilenya bandwagon yet. As much as I hate my needles, the auto-injector at least makes the process bearable, even if I flinch every time I push that button. Competing therapies are even worse: Avonex by Biogen Idec
A pill such as Gilenya would be nice -- if early tests hadn't shown side effects like possible liver damage and bradycardia. The drug was first intended to treat rejection of kidney transplants, but was rejected because it was too toxic at the required dosage levels. The MS-approved dosage is far smaller, but do I really want to put toxins in my system on a daily basis, even at low levels?
So I'm staying in the Copaxone camp because I don't like side effects, and many fellow MS patients are probably thinking the same thing. That doesn't mean that Teva can rest easy, and the company is in fact working on an MS pill of its own together with privately held Active Biotech. Other pills are being developed by sanofi-aventis
For now, I'm dealing with the Copaxone and actively enjoying the effects of my Ampyra pills from Acorda Therapeutics
Until then, Copaxone remains the leading MS therapy and keeps growing its sales quarter by quarter. Enjoy that while it lasts, Teva. Unfortunately for Novartis, I agree with Brian's conclusion that Gilenya's success could be short-lived.
Fool contributor Anders Bylund holds no position in any of the companies discussed here. UnitedHealth Group is a Motley Fool Inside Value recommendation and a Motley Fool Stock Advisor selection. Elan is a Motley Fool Rule Breakers pick. Novartis is a Motley Fool Global Gains recommendation. Motley Fool Options has recommended a diagonal call position on UnitedHealth Group. The Fool owns shares of Teva Pharmaceutical and UnitedHealth Group. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. You can check out Anders' holdings and a concise bio if you like, and The Motley Fool is investors writing for investors.